Nineteen abstracts to be presented, including new post-hoc sub-analyses from the ARISTOTLE Phase 3 trial and multiple retrospective real-world data analyses from ACROPOLIS
Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 | BMS Newsroom
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.